| Autor: |
Kerrick Hesse |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
American Heart Journal Plus, Vol 23, Iss , Pp 100218- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2666-6022 |
| DOI: |
10.1016/j.ahjo.2022.100218 |
| Popis: |
The rates of atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) continue to grow with many patients suffering from their combined impact on quality of life and prognosis.A lower heart rate (HR) in HFrEF is associated with reduced morbidity and mortality due to beta-blocker and ivabradine therapy. Postulated mechanisms include reduced neurohumoral activation, increased diastolic filling time and myocardial energy conservation. In contrast, the landmark randomised controlled non-inferiority RACE II trial demonstrated that a lenient rate control strategy (target HR |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
